贝瑞基因(000710) - 2018 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2018 was ¥297,185,149.31, representing a 32.18% increase compared to ¥224,832,468.27 in the same period last year[8] - Net profit attributable to shareholders was ¥65,667,179.26, a significant increase of 69.37% from ¥38,770,309.41 year-on-year[8] - The net profit after deducting non-recurring gains and losses was ¥65,828,456.68, reflecting a 71.95% increase compared to ¥38,282,700.64 in the previous year[8] - The net cash flow from operating activities was ¥40,157,828.41, improving from a negative cash flow of -¥57,539,539.87 in the same period last year[8] - The weighted average return on equity was 4.18%, up from 2.94% in the same period last year, an increase of 1.24%[8] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,794,600,607.50, a slight decrease of 0.65% from ¥1,806,398,388.71 at the end of the previous year[8] - The net assets attributable to shareholders increased by 4.61% to ¥1,607,354,392.34 from ¥1,536,563,885.71 at the end of the previous year[8] Expenses - Management expenses increased by 40.86% year-on-year, primarily due to higher audit fees and employee salary adjustments[15] - Financial expenses decreased by 578.42% year-on-year, attributed to the determination of interest on time deposits[15] - The company reported a 92.98% increase in asset impairment losses compared to the previous year, mainly due to increased provisions for bad debts[15] Future Projections - The estimated cumulative net profit for the period from the beginning of the year to the next reporting period is projected to be a loss of 13,000,000 RMB, representing a decrease of 1,865.92% compared to the same period last year[17] - The basic earnings per share (EPS) is expected to be 0.3666 RMB, reflecting a decrease of 833.20% compared to the previous year's EPS of 0.4230 RMB[17] Strategic Developments - The company completed a significant asset restructuring with Beijing Berry Genomics Co., Ltd. on August 10, 2017, which will affect the financial reporting for the first half of 2018[18] - The company anticipates continued growth in its medical products and services, as well as basic research services, compared to the same period last year due to competitive advantages in technology, products, and brand[18]